Clinical Trial Update: Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer [NA]

View source ↗

Summary

This is a completed pilot trial evaluating veliparib in combination with lapatinib in patients with metastatic triple-negative breast cancer; results have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Tykerb (lapatinib)
• Veliparib (veliparib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Metastatic Triple Negative Breast Cancer | NA | Status: COMPLETED | Results posted: 2026-01-22